Jan 29, 08
|
| NEW STORY |
| 08:00 ET |
Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
|
|
Jan 28, 08
|
| NEW STORY |
| 08:00 ET |
Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
|
|
Jan 07, 08
|
| 08:00 ET |
Allos Therapeutics Initiates Phase 2b Study of PDX in Patients With Non-small Cell Lung Cancer
|
|
Dec 27, 07
|
| 08:00 ET |
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
|
|
Dec 11, 07
|
| 08:00 ET |
Allos Therapeutics to Present at the 2008 JPMorgan Healthcare Conference
|
|
Dec 05, 07
|
| 08:00 ET |
Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference
|
|
Nov 29, 07
|
| 08:00 ET |
Allos Therapeutics to Present at the 2007 BMO Capital Markets Focus on Healthcare Conference
|
|
Nov 20, 07
|
| 08:00 ET |
Allos Therapeutics to Present at the 2007 Lazard Capital Markets Healthcare Investor Conference
|
|
Nov 12, 07
|
| 16:00 ET |
Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma
|
|
Nov 07, 07
|
| 16:00 ET |
Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference
|
|
Nov 05, 07
|
| 07:30 ET |
Allos Therapeutics Reports Third Quarter 2007 Financial Results
|
|
Oct 31, 07
|
| 08:00 ET |
Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference
|
|
Oct 25, 07
|
| 16:01 ET |
Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
|
|
Oct 16, 07
|
| 07:55 ET |
Allos Therapeutics to Report 2007 Third Quarter Financial Results on November 5, 2007
|
|
Sep 24, 07
|
| 07:30 ET |
Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
|
|
Sep 13, 07
|
| 08:00 ET |
Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
|
|
Sep 04, 07
|
| 08:00 ET |
Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference
|
|
Aug 15, 07
|
| 08:00 ET |
Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
|
|
Aug 07, 07
|
| 08:00 ET |
Allos Therapeutics Reports Second Quarter 2007 Financial Results
|
|
Jul 18, 07
|
| 08:00 ET |
Allos Therapeutics to Report 2007 Second Quarter Financial Results on August 7, 2007
|
|
Jun 25, 07
|
| 08:30 ET |
Allos Therapeutics Selected to Join Russel 3000 Index
|
|
Jun 19, 07
|
| 05:30 ET |
Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
|
|
May 31, 07
|
| 16:01 ET |
Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
|
|
May 23, 07
|
| 16:55 ET |
Allos Therapeutics Files Shelf Registration Statement
|
|
May 08, 07
|
| 07:30 ET |
Allos Therapeutics Reports First Quarter 2007 Financial Results
|
|
May 01, 07
|
| 12:21 ET |
Allos Therapeutics to Announce 2007 First Quarter Results on Tuesday, May 8
|
|
Apr 26, 07
|
| 07:00 ET |
Allos Therapeutics Appoints Dr. Jeffrey R. Latts to Its Board of Directors
|
|
Apr 19, 07
|
| 07:30 ET |
Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission
|
|
Mar 20, 07
|
| 07:00 ET |
Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical Officer
|
|
Mar 05, 07
|
| 07:00 ET |
Allos Therapeutics Reports Fourth Quarter and 2006 Financial Results
|
|
Feb 27, 07
|
| 08:00 ET |
Allos Therapeutics to Report 2006 Fourth Quarter Financial Results on Monday, March 5
|
|
Feb 13, 07
|
| 08:00 ET |
Allos Therapeutics to Present at Upcoming Investor Conferences
|
|
Feb 02, 07
|
| 11:01 ET |
Allos Therapeutics Announces Closing of Common Stock Offering
|
|
Jan 30, 07
|
| 06:00 ET |
Allos Therapeutics Announces Pricing of Underwritten Offering of 9,000,000 Shares of Common Stock
|
|
Jan 08, 07
|
| 15:19 ET |
Allos Therapeutics to Present at the 2007 JP Morgan Healthcare Conference
|
|
| 07:05 ET |
Allos Therapeutics Appoints William R. Ringo to Its Board of Directors
|
|
| 07:00 ET |
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in Patients With Peripheral T-cell Lymphoma
|
|
Dec 11, 06
|
| 11:46 ET |
Results Reported at the American Society of Hematology Annual Meeting Affirm Impressive Activity of Allos Therapeutics' Novel Antifolate PDX in Patients with Peripheral T-Cell Lymphoma
|
|
Nov 20, 06
|
| 08:00 ET |
Allos Therapeutics Added to NASDAQ Biotech Index
|
|
Nov 10, 06
|
| 08:15 ET |
Updated Safety Analysis of Allos Therapeutics Phase 1/2 Study of PDX in Patients With Aggressive Lymphomas Demonstrates Decreased Incidence of Stomatitis With Vitamin Pre-Treatment and Weekly Dosing Schedule
|
|
Nov 09, 06
|
| 13:56 ET |
Allos Therapeutics Announces Presentation of Updated Results From Phase 1/2 Trial of PDX in Patients With Aggressive Lymphomas at the 2006 American Society of Hematology Annual Meeting
|
|
Nov 06, 06
|
| 12:00 ET |
Updated Analysis Demonstrates Long-Term Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential Chemoradiotherapy
|
|
Nov 03, 06
|
| 07:30 ET |
Allos Therapeutics Reports Third Quarter 2006 Financial Results
|
|
Nov 01, 06
|
| 16:00 ET |
Allos Therapeutics to Announce 2006 Third Quarter Financial Results on Friday, November 3
|
|
Oct 31, 06
|
| 12:30 ET |
Allos Therapeutics Announces Presentations on EFAPROXYN(TM) and PDX at Upcoming Scientific Conferences
|
|
Oct 23, 06
|
| 06:29 ET |
Allos Therapeutics Announces ENRICH Trial Update
|
|
Oct 03, 06
|
| 08:00 ET |
Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell Lymphoma
|
|
Aug 29, 06
|
| 07:30 ET |
Allos Therapeutics to Present at Upcoming Investor Conferences
|
|
| 07:00 ET |
Allos Therapeutics Initiates Pivotal Phase 2 Study of PDX in Patients With Peripheral T-cell Lymphoma
|
|
Aug 28, 06
|
| 07:00 ET |
Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Study of EFAPROXYN(TM) in Women with Brain Metastases Originating from Breast Cancer
|
|
Aug 07, 06
|
| 07:00 ET |
Allos Therapeutics Reports Second Quarter 2006 Financial Results
|
|
Aug 02, 06
|
| 07:30 ET |
Allos Therapeutics Receives Special Protocol Assessment for Pivotal Phase 2 Study of the Company's Novel Antifolate PDX in Patients with Peripheral T-cell Lymphoma
|
|
Jul 26, 06
|
| 08:00 ET |
FDA Grants Orphan Drug Designation to Allos Therapeutics' Novel Antifolate PDX for the Treatment of T-cell Lymphoma
|
|
Jun 14, 06
|
| 07:00 ET |
Retrospective Analysis of Allos Therapeutics' Phase 3 REACH Study Finds Positive Correlation between Patient Outcomes and EFAPROXYN(TM) (efaproxiral) Exposure in Patients with Brain Metastases from Breast and Non-Small Cell Lung Cancers
|
|
Jun 13, 06
|
| 07:12 ET |
Allos Therapeutics Files Shelf Registration Statement
|
|
Jun 07, 06
|
| 08:00 ET |
Allos Therapeutics to Present at the 2006 Needham & Company Biotechnology Conference
|
|
Jun 05, 06
|
| 18:07 ET |
Allos Therapeutics Appoints James V. Caruso as Chief Commercial Officer
|
|
| 08:00 ET |
Allos Therapeutics' EFAPROXYN(TM) Found to Reduce Tumor Hypoxia and HIF-1-alpha Expression in Human Breast Cancer Xenografts
|
|
May 25, 06
|
| 15:33 ET |
Allos Therapeutics Reports Restricted Stock Grant Under Nasdaq Marketplace Rule 4350
|
|
May 09, 06
|
| 07:00 ET |
Allos Therapeutics Reports First Quarter 2006 Financial Results
|
|
Apr 04, 06
|
| 07:00 ET |
Interim Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 3 Trial
|
|
Mar 10, 06
|
| 08:01 ET |
Allos Therapeutics Appoints Paul L. Berns as President and CEO
|
|
Mar 06, 06
|
| 08:03 ET |
Allos Therapeutics Reports 2005 Financial Results
|
|
Mar 01, 06
|
| 08:01 ET |
Allos Therapeutics to Present at the 2006 Cowen Healthcare Conference
|
|
Feb 14, 06
|
| 08:12 ET |
Scheduled Combination of Allos Therapeutics' Pralatrexate Plus Gemcitabine Proves Superior to Methotrexate Plus Cytarabine in Models of Human Non-Hodgkin's Lymphoma
|
|
Feb 01, 06
|
| 08:03 ET |
Allos Therapeutics to Present at the 2006 BIO CEO & Investor Conference
|
|
Jan 16, 06
|
| 19:22 ET |
Allos Therapeutics Announces CEO Succession Plans
|
|
Jan 03, 06
|
| 08:00 ET |
Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases Originating From Breast Cancer
|
|
Dec 12, 05
|
| 08:05 ET |
PDX Shows Promising Activity in Patients With Resistant T-Cell Lymphomas
|
|
| 08:02 ET |
Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality of Life in Patients With Brain Metastases Originating From Breast Cancer
|
|
Nov 17, 05
|
| 08:02 ET |
Allos Therapeutics Appoints Timothy P. Lynch to Board of Directors
|
|
| 08:01 ET |
Interim Phase 1 Data on RH1 Presented at AACR-NCI-EORTC Conference
|
|
Nov 16, 05
|
| 08:00 ET |
Data From Phase 1 Clinical Trial of PDX (Pralatrexate) to be Presented at American Society of Hematology Annual Meeting
|
|
Nov 09, 05
|
| 08:04 ET |
Allos Therapeutics Reports Third Quarter 2005 Financial Results
|
|
Nov 08, 05
|
| 08:03 ET |
Data on EFAPROXYN(TM) and RH1 to be Presented at Upcoming Scientific Conferences
|
|
Oct 21, 05
|
| 11:02 ET |
Allos Therapeutics Announces Dismissal of Securities Class Action Lawsuit
|
|
Oct 13, 05
|
| 08:01 ET |
Allos Therapeutics to Present at the 2005 BIO Investor Forum
|
|
Oct 11, 05
|
| 17:06 ET |
Allos Therapeutics Announces Withdrawal of European Marketing Authorization Application for REVAPROXYN(TM)
|
|
Sep 22, 05
|
| 08:03 ET |
Allos Therapeutics to Present at the UBS Global Life Sciences Conference
|
|
Sep 07, 05
|
| 08:03 ET |
Allos Therapeutics to Present at the Bear Stearns Healthcare Conference
|
|
Sep 01, 05
|
| 08:01 ET |
Results Published in Journal of Clinical Oncology Demonstrate Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential Chemoradiotherapy
|
|
Aug 08, 05
|
| 08:03 ET |
Allos Therapeutics Reports Second Quarter 2005 Financial Results
|
|
Jun 16, 05
|
| 14:28 ET |
Allos Therapeutics and Hovione Enter Into Manufacturing Agreement for EFAPROXYN(TM) Bulk Drug Substance
|
|
May 19, 05
|
| 17:46 ET |
Allos Therapeutics Announces Stockholder Approval of Share Exchange
|
|
| 08:00 ET |
Allos Therapeutics to Present at the Needham & Company Biotechnology Conference
|
|
May 05, 05
|
| 08:14 ET |
Allos Therapeutics Reports First Quarter 2005 Financial Results
|
|